Screening for Growth-Factor Combinations Enabling Synergistic Differentiation of Human MSC to Nucleus Pulposus Cell-Like Cells
Source abstract
Abstract
Background: Multiple studies have examined the potential of growth factors (GF) to enable mesenchymal stromal cells (MSC) to nucleus pulposus (NP) cell-like cell differentiation. Here we screened a wide range of GF and GF combinations for supporting NP cell-like cell differentiation. Methods: Human MSC were stimulated using 86 different GF combinations of TGF-β1, -2, -3, GDF5, -6, Wnt3a, -5a, -11, and Shh. Differentiation potency was assessed by alcian blue assay and NP cell marker expression (e.g., COL2A1, CD24, etc.). The top four combinations and GDF5/TGF-β1 were further analyzed in 3D pellet cultures, on their ability to similarly induce NP cell differentiation. Results: Almost all 86 GF combinations showed their ability to enhance proteoglycan production in alcian blue assay. Subsequent qPCR analysis revealed TGF-β2/Wnt3a, TGF-β1/Wnt3a, TGF-β1/Wnt3a/GDF6, and Wnt3a/GDF6 as the most potent combinations. Although in pellet cultures, these combinations supported NP marker expression, none showed the ability to significantly induce chondrogenic NP matrix production. Only GDF5/TGF-β1 resulted in chondrogenic pellets with significantly enhanced glycosaminoglycan content. Conclusion: GDF5/TGF-β1 was suggested as an optimal GF combination for MSC to NP cell induction, although further assessment using a 3D and in vivo environment is required. Wnt3a proved promising for monolayer-based NP cell differentiation, although further validation is required.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Spine and Intervertebral Disc Pathology · Mesenchymal stem cell research · Liver physiology and pathology
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Orthopaedic Surgery, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan
Department of Biomedical Engineering, Eindhoven University of Technology, 5612AZ Eindhoven, The Netherlands
Center for Musculoskeletal Innovative Research and Advancement (C-MiRA), Tokai University Graduate School, 143 Shimokasuya, Isehara, Kanagawa 259-1193, Japan
References (66)
Show source-provided references
1. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: A systematic analysis for the Global Burden of Disease Study 201510.1016/S0140-6736(16)31678-6 ↗
2. Cell therapy for intervertebral disc herniation and degenerative disc disease: Clinical trials10.1007/s00264-018-4223-1 ↗
3. Smith, L.J., Silverman, L., Sakai, D., Le Maitre, C.L., Mauck, R.L., Malhotra, N.R., Lotz, J.C., and Buckley, C.T. (2018). Advancing cell therapies for intervertebral disc regeneration from the lab to the clinic: Recommendations of the ORS spine section. JOR Spine, 1.10.1002/jsp2.1036 ↗
4. Thorpe, A.A., Bach, F.C., Tryfonidou, M.A., Le Maitre, C.L., Mwale, F., Diwan, A.D., and Ito, K. (2018). Leaping the hurdles in developing regenerative treatments for the intervertebral disc from preclinical to clinical. JOR Spine, 1.10.1002/jsp2.1027 ↗
5. Oichi, T., Taniguchi, Y., Oshima, Y., Tanaka, S., and Saito, T. (2020). Pathomechanism of intervertebral disc degeneration. JOR Spine, 3.10.1002/jsp2.1076 ↗
6. Mechanics and biology in intervertebral disc degeneration: A vicious circle10.1016/j.joca.2015.03.028 ↗
7. Zeldin, L., Mosley, G.E., Laudier, D., Gallate, Z.S., Gansau, J., Hoy, R.C., Poeran, J., and Iatridis, J.C. (2020). Spatial mapping of collagen content and structure in human intervertebral disk degeneration. JOR Spine, 3.10.1002/jsp2.1129 ↗
8. Fournier, D.E., Kiser, P.K., Shoemaker, J.K., Battie, M.C., and Seguin, C.A. (2020). Vascularization of the human intervertebral disc: A scoping review. JOR Spine, 3.10.1002/jsp2.1123 ↗
9. Vincent, K., Dona, C.P.G., Albert, T.J., and Dahia, C.L. (2020). Age-related molecular changes in the lumbar dorsal root ganglia of mice: Signs of sensitization, and inflammatory response. JOR Spine, 3.10.1002/jsp2.1124 ↗
10. Ma, J., Stefanoska, D., Stone, L.S., Hildebrand, M., van Donkelaar, C.C., Zou, X., Basoli, V., Grad, S., Alini, M., and Peroglio, M. (2020). Hypoxic stress enhances extension and branching of dorsal root ganglion neuronal outgrowth. JOR Spine, 3.10.1002/jsp2.1090 ↗
11. Role of cytokines in intervertebral disc degeneration: Pain and disc content10.1038/nrrheum.2013.160 ↗
12. The role of structure and function changes of sensory nervous system in intervertebral disc-related low back pain10.1016/j.joca.2020.09.002 ↗
13. Complications in lumbar fusion surgery for chronic low back pain: Comparison of three surgical techniques used in a prospective randomized study. A report from the Swedish Lumbar Spine Study Group10.1007/s00586-002-0493-8 ↗
14. Adjacent segment disease after instrumented fusion for adult lumbar spondylolisthesis: Incidence and risk factors10.1016/j.clineuro.2017.02.020 ↗
15. North American Spine Society (2020). Diagnosis and Treatment of Low Back Pain, NASS.
16. Krupkova, O., Cambria, E., Besse, L., Besse, A., Bowles, R., and Wuertz-Kozak, K. (2018). The potential of CRISPR/Cas9 genome editing for the study and treatment of intervertebral disc pathologies. JOR Spine, 1.10.1002/jsp2.1003 ↗
17. Therapeutic potential of growth differentiation factors in the treatment of degenerative disc diseases10.1002/jsp2.1045 ↗
18. Biomaterials for intervertebral disc regeneration and repair10.1016/j.biomaterials.2017.03.013 ↗
19. Growing a backbone—Functional biomaterials and structures for intervertebral disc (IVD) repair and regeneration: Challenges, innovations, and future directions10.1039/C9BM01288E ↗
20. Gullbrand, S.E., Smith, L.J., Smith, H.E., and Mauck, R.L. (2018). Promise, progress, and problems in whole disc tissue engineering. JOR Spine, 1.10.1002/jsp2.1015 ↗
21. Buckley, C.T., Hoyland, J.A., Fujii, K., Pandit, A., Iatridis, J.C., and Grad, S. (2018). Critical aspects and challenges for intervertebral disc repair and regeneration-Harnessing advances in tissue engineering. JOR Spine, 1.10.1002/jsp2.1029 ↗
22. Stem cell therapy for intervertebral disc regeneration: Obstacles and solutions10.1038/nrrheum.2015.13 ↗
23. Hiraishi, S., Schol, J., Sakai, D., Nukaga, T., Erickson, I., Silverman, L., Foley, K., and Watanabe, M. (2018). Discogenic cell transplantation directly from a cryopreserved state in an induced intervertebral disc degeneration canine model. JOR Spine, 1.10.1002/jsp2.1013 ↗
24. Nukaga, T., Sakai, D., Schol, J., Sato, M., and Watanabe, M. (2019). Annulus fibrosus cell sheets limit disc degeneration in a rat annulus fibrosus injury model. JOR Spine, 2.10.1002/jsp2.1050 ↗
25. Disc cell therapy with bone-marrow-derived autologous mesenchymal stromal cells in a large porcine disc degeneration model10.1007/s00586-018-5728-4 ↗
26. Cell therapy for intervertebral disc repair: Clinical perspective
27. The Pros and Cons of Mesenchymal Stem Cell-Based Therapies10.1177/0963689719837897 ↗
28. Minimal Sustainability of Dedifferentiation by ROCK Inhibitor on Rat Nucleus Pulposus Cells In Vitro10.22603/ssrr.2019-0019 ↗
29. Sakai, D., Schol, J., Bach, F.C., Tekari, A., Sagawa, N., Nakamura, Y., Chan, S.C.W., Nakai, T., Creemers, L.B., and Frauchiger, D.A. (2018). Successful fishing for nucleus pulposus progenitor cells of the intervertebral disc across species. JOR Spine, 1.10.1002/jsp2.1018 ↗
30. Loibl, M., Wuertz-Kozak, K., Vadala, G., Lang, S., Fairbank, J., and Urban, J.P. (2019). Controversies in regenerative medicine: Should intervertebral disc degeneration be treated with mesenchymal stem cells?. JOR Spine, 2.10.1002/jsp2.1043 ↗
31. Vickers, L., Thorpe, A.A., Snuggs, J., Sammon, C., and Le Maitre, C.L. (2019). Mesenchymal stem cell therapies for intervertebral disc degeneration: Consideration of the degenerate niche. JOR Spine, 2.10.1002/jsp2.1055 ↗
32. Allogeneic mesenchymal precursor cells treatment for chronic low back pain associated with degenerative disc disease: A prospective randomized, placebo-controlled 36-month study of safety and efficacy10.1016/j.spinee.2020.10.004 ↗
33. Effects of hypoxia on differentiation from human placenta-derived mesenchymal stem cells to nucleus pulposus-like cells10.1016/j.spinee.2014.03.028 ↗
34. Influence of different commercial scaffolds on the in vitro differentiation of human mesenchymal stem cells to nucleus pulposus-like cells10.1007/s00586-011-1975-3 ↗
35. Differentiation of MSC and annulus fibrosus cells on genetically engineered silk fleece-membrane-composites enriched for GDF-6 or TGF-beta310.1002/jor.23778 ↗
36. Directed Differentiation of Notochord-like and Nucleus Pulposus-like Cells Using Human Pluripotent Stem Cells10.1016/j.celrep.2020.01.100 ↗
37. Bucher, C., Gazdhar, A., Benneker, L.M., Geiser, T., and Gantenbein-Ritter, B. (2013). Nonviral Gene Delivery of Growth and Differentiation Factor 5 to Human Mesenchymal Stem Cells Injected into a 3D Bovine Intervertebral Disc Organ Culture System. Stem Cells Int., 2013.10.1155/2013/326828 ↗
38. Defining the phenotype of young healthy nucleus pulposus cells: Recommendations of the Spine Research Interest Group at the 2014 annual ORS meeting10.1002/jor.22789 ↗
39. Long-term expansion, enhanced chondrogenic potential, and suppression of endochondral ossification of adult human MSCs via WNT signaling modulation10.1016/j.stemcr.2015.01.017 ↗
40. The Wnt5a Receptor, Receptor Tyrosine Kinase-Like Orphan Receptor 2, Is a Predictive Cell Surface Marker of Human Mesenchymal Stem Cells with an Enhanced Capacity for Chondrogenic Differentiation10.1002/stem.2691 ↗
41. TGF beta-1 administration during ex vivo expansion of human articular chondrocytes in a serum-free medium redirects the cell phenotype toward hypertrophy10.1002/jcp.24024 ↗
42. Expansion on a matrix deposited by nonchondrogenic urine stem cells strengthens the chondrogenic capacity of repeated-passage bone marrow stromal cells10.1007/s00441-014-1801-4 ↗
43. Role of hypoxia and growth and differentiation factor-5 on differentiation of human mesenchymal stem cells towards intervertebral nucleus pulposus-like cells10.22203/eCM.v021a40 ↗
44. Clarke, L.E., McConnell, J.C., Sherratt, M.J., Derby, B., Richardson, S.M., and Hoyland, J.A. (2014). Growth differentiation factor 6 and transforming growth factor-beta differentially mediate mesenchymal stem cell differentiation, composition, and micromechanical properties of nucleus pulposus constructs. Arthritis Res. Ther., 16.10.1186/ar4505 ↗
45. Microparticles for controlled growth differentiation factor 6 delivery to direct adipose stem cell-based nucleus pulposus regeneration10.1002/term.2882 ↗
46. Hodgkinson, T., Wignall, F., Hoyland, J.A., and Richardson, S.M. (2020). High BMPR2 expression leads to enhanced SMAD1/5/8 signalling and GDF6 responsiveness in human adipose-derived stem cells: Implications for stem cell therapies for intervertebral disc degeneration. J. Tissue Eng., 11.10.1177/2041731420919334 ↗
47. TGF-beta1 and GDF5 Act Synergistically to Drive the Differentiation of Human Adipose Stromal Cells toward Nucleus Pulposus-like Cells10.1002/stem.2249 ↗
48. Wnt3a and wnt5a as Potential Chondrogenic Stimulators for Nucleus Pulposus Cell Induction: A Comprehensive Review10.14245/ns.2040040.020 ↗
49. Intervertebral disc repair with activated nucleus pulposus cell transplantation: A three-year, prospective clinical study of its safety10.22203/eCM.v029a15 ↗
50. Regeneration of Articular Cartilage by Human ESC-Derived Mesenchymal Progenitors Treated Sequentially with BMP-2 and Wnt5a10.5966/sctm.2016-0020 ↗
51. Effects of plating density and culture time on bone marrow stromal cell characteristics10.1016/j.exphem.2008.03.019 ↗
52. Long-term culture in vitro impairs the immunosuppressive activity of mesenchymal stem cells on T cells10.3892/mmr.2012.1039 ↗
53. Kretlow, J.D., Jin, Y.Q., Liu, W., Zhang, W.J., Hong, T.H., Zhou, G., Baggett, L.S., Mikos, A.G., and Cao, Y. (2008). Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol., 9.10.1186/1471-2121-9-60 ↗
54. Fearing, B.V., Hernandez, P.A., Setton, L.A., and Chahine, N.O. (2018). Mechanotransduction and cell biomechanics of the intervertebral disc. JOR Spine, 1.10.1002/jsp2.1026 ↗
55. Interactions between extracellular matrix and growth factors in wound healing10.1111/j.1524-475X.2009.00466.x ↗
56. Ravalli, S., Szychlinska, M.A., Lauretta, G., and Musumeci, G. (2020). New Insights on Mechanical Stimulation of Mesenchymal Stem Cells for Cartilage Regeneration. Appl. Sci., 10.10.3390/app10082927 ↗
57. Transforming growth factor-beta and notch signaling mediate stem cell differentiation into smooth muscle cells10.1002/stem.319 ↗
58. Elsafadi, M., Manikandan, M., Almalki, S., Mobarak, M., Atteya, M., Iqbal, Z., Hashmi, J.A., Shaheen, S., Alajez, N., and Alfayez, M. (2018). TGFbeta1-Induced Differentiation of Human Bone Marrow-Derived MSCs Is Mediated by Changes to the Actin Cytoskeleton. Stem Cells Int., 2018.10.1155/2018/6913594 ↗
59. Mohamed-Ahmed, S., Fristad, I., Lie, S.A., Suliman, S., Mustafa, K., Vindenes, H., and Idris, S.B. (2018). Adipose-derived and bone marrow mesenchymal stem cells: A donor-matched comparison. Stem Cell Res. Ther., 9.10.1186/s13287-018-0914-1 ↗
60. Enhancement of intervertebral disc cell senescence by WNT/beta-catenin signaling-induced matrix metalloproteinase expression10.1002/art.27599 ↗
61. The relationship between the Wnt/beta-catenin and TGF-beta/BMP signals in the intervertebral disc cell10.1002/jcp.22438 ↗
62. Wnt signaling in cartilage development and diseases: Lessons from animal studies10.1038/labinvest.2015.142 ↗
63. Wnt-3A enhances bone morphogenetic protein-2-mediated chondrogenesis of murine C3H10T1/2 mesenchymal cells10.1074/jbc.M109330200 ↗
64. Croft, A.S., Guerrero, J., Oswald, K.A.C., Häckel, S., Albers, C.E., and Gantenbein, B. (2021). Effect of different cryopreservation media on human nucleus pulposus cells’ viability and trilineage potential. JOR Spine.10.1002/jsp2.1140 ↗
65. Elabd, C., Centeno, C.J., Schultz, J.R., Lutz, G., Ichim, T., and Silva, F.J. (2016). Intra-discal injection of autologous, hypoxic cultured bone marrow-derived mesenchymal stem cells in five patients with chronic lower back pain: A long-term safety and feasibility study. J. Transl. Med., 14.10.1186/s12967-016-1015-5 ↗
66. Identifying and Managing Sources of Variability in Cell Therapy Manufacturing and Clinical Trials10.1007/s40883-019-00129-y ↗